IGC Pharma, Inc. (IGC) Stock Price

IGCStock

$0.25−38.68%52W

Market Cap$25.43M

P/E—

PEG Ratio—

Div yield—

Beta0.52

IGC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.58%

Price vs S&P 500 (4W)-8.89%

VGM Score37.09

Book Value / Share (Quarterly)$0.06

P/TBV (Annual)11.25x

Revenue Growth (3Y)-1.52%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-24.51%

Gross Margin (TTM)21.91%

Net Profit Margin (TTM)-702.14%

EPS (TTM)$-0.08

10-Day Avg Trading Volume0.72M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)-0.70%

EPS (Annual)$-0.05

ROI (Annual)-54.86%

Gross Margin (Annual)34.18%

Net Profit Margin (5Y Avg)-1404.75%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)-19.21%

ROA (Last FY)-42.69%

Revenue Growth TTM (YoY)-15.37%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-97.20%

Operating Margin (TTM)-986.82%

Cash Flow / Share (Annual)$-0.06

P/B Ratio4.15x

P/B Ratio (Quarterly)4.63x

Net Income / Employee (Annual)$-59,200

EV / Revenue (TTM)23.32x

Net Interest Coverage (TTM)-58.67x

ROA (TTM)-82.70%

EV / EBITDA (TTM)8.23x

EPS Incl Extra (Annual)$-0.05

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)0.14x

3-Month Avg Trading Volume0.66M

52-Week Price Return-38.68%

Revenue / Employee (TTM)$16,000

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)29.27x

Asset Turnover (Annual)0.09x

52-Week High$0.45

Operating Margin (5Y Avg)-1519.14%

EPS Excl Extra (Annual)$-0.05

CapEx CAGR (5Y)-16.30%

Tangible BV CAGR (5Y)-40.97%

26-Week Price Return-20.67%

Quick Ratio (Annual)0.47x

13-Week Price Return-5.38%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.39x

Enterprise Value$26.18M

Revenue / Share Growth (5Y)-14.46%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-35.25%

Revenue / Employee (Annual)$12,400

Inventory Turnover (Annual)0.45x

Pretax Margin (Annual)-477.10%

Cash / Share (Annual)$0.01

3-Month Return Std Dev51.57%

Gross Margin (5Y Avg)46.65%

Net Income / Employee (TTM)$-112,600

ROE (Last FY)-55.85%

Net Interest Coverage (Annual)-7.57x

EPS Basic Excl Extra (Annual)$-0.05

P/FCF (TTM)94.19x

Receivables Turnover (TTM)15.71x

Total Debt / Equity (Quarterly)0.18x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)34.82x

ROI (TTM)-105.00%

P/S Ratio (TTM)22.65x

Pretax Margin (5Y Avg)-1404.75%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-54.22%

Year-to-Date Return-12.58%

5-Day Price Return-10.87%

EPS Normalized (Annual)$-0.05

ROA (5Y Avg)-75.67%

Net Profit Margin (Annual)-477.10%

Month-to-Date Return-8.52%

Cash Flow / Share (TTM)$-0.19

EBITD / Share (Annual)$-0.08

Operating Margin (Annual)-891.25%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-95.63%

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-0.08

P/TBV (Quarterly)45.42x

P/B Ratio (Annual)3.52x

Inventory Turnover (TTM)0.88x

Pretax Margin (TTM)-702.14%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-8.07%

Beta0.52x

Revenue / Share (TTM)$0.01

ROE (TTM)-113.58%

52-Week Low$0.23

vGradeD

gGradeD

mGradeC

vgmGradeD

IGC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$0.02	-$0.03	-50.00%(-$0.01)
Q1 2026	May 15, 2026	-$0.02	-$0.02	+0.00%(+$0.00)
Q1 2025	Jun 27, 2025	-$0.02	-$0.01	+50.00%(+$0.01)
Q4 2024	Feb 14, 2025	-$0.03	-$0.02	+33.33%(+$0.01)
Q3 2024	Nov 12, 2024	-$0.03	-$0.02	+33.33%(+$0.01)

IGC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IGCIGC Pharma, Inc.	D	D	C	22.6x	-15.4%	21.9%	—	$0.25
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About IGC Pharma, Inc.

IGC Pharma develops cannabinoid-based therapeutics for neurological and pain disorders. The company's Alzheimer's disease program includes four investigational candidates (IGC-AD1, IGC-M3, IGC-1C, and TGR-63) that have demonstrated preclinical potential to reduce amyloid plaques and tau tangles. Additional pipeline programs target period cramps, premenstrual syndrome, and chronic pain.